Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/jRCT2051240070
jRCT2051240070Active, not recruitingNot Applicable

Phase 3, multicenter, open-label, single-arm study to evaluate the efficacy and safety of RE-021 in Japanese patients with IgA nephropathy

Renalys Pharma, Inc.0 sites30 target enrollmentStarted: July 16, 2024Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
30
Primary Endpoint
Change from baseline in urinary protein-to-creatinine ratio (UP/C)
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Single Arm Study
Intervention Model
Single Assignment
Primary Purpose
Treatment Purpose
Masking
Open(masking Not Used)

Eligibility Criteria

Ages
10age old over to No limit (—)
Sex
All

Inclusion Criteria

  • •Patients who meet all of the following criteria will be included.
  • •Outpatients aged 10 years or older at the time of signing the ICF
  • •Patients diagnosed with primary IgA nephropathy by renal biopsy performed in the past
  • •Patients with urinary protein >= 0.5 g/day at screening
  • •Patients with eGFR >= 30 mL/min/1.73 m2 at screening
  • •Patients receiving an SGLT2 inhibitor who have been receiving the same SGLT2 inhibitor continuously for at least 24 weeks before the screening test and at a constant dose for 12 weeks before screening
  • •Patients who consent to contraception
  • •Patients who can sign the ICF as described in the section on procedures for obtaining consent, including compliance with the requirements and restrictions described in the ICF and the protocol. (In the case of minors, signatures by Ascent and Substitute).
  • •Patient using Angiotensin-converting enzyme inhibition at the same dosage and administration (maximum tolerated capacity and >= 1/2 of the maximum approved dose) for at least 12 weeks before the screening test (ACEI) and/or angiotensin n-receptor blockers (ARBs).

Exclusion Criteria

  • •Patients should be excluded from the study if any of the following criteria are met
  • •Patients with IgA nephropathy due to other diseases (Systemic lupus erythematosus, cirrhosis, etc.) or IgA vasculitis (Henoch-Schonlein purpura)
  • •Patients who underwent palatine tonsillectomy within 2 years before screening. Patients who plan to undergo palatine tonsillectomy during the study period.
  • •Patients with more than 25% of the glomeruli identified as cellular glomerular crescents if a renal biopsy was performed within 6 months before the screening test.
  • •Patients with IgA nephropathy plus other chronic kidney diseases, such as diabetic nephropathy.
  • •Patients with a history of organ transplantation, excluding corneal transplantation
  • •Patients who need to continue concomitant prohibited drugs
  • •Clinically significant cerebrovascular disease (transient ischemic attack or stroke) and/or coronary artery disease (myocardial infarction or Hospitalization for unstable angina, new onset of angina with a positive functional test, coronary angiographic evidence of stenosis, or need for coronary revascularization)
  • •Diagnosis of jaundice, hepatitis, or other hepatobiliary disease or liver function tests at screening [alanine aminotransferase (ALT) or aspartate aminotransferase (AST)] > 2 times the upper limit of normal
  • •Patients diagnosed with malignancy within 2 years prior to consent (Excludes appropriately treated basal cell carcinoma, squamous skin carcinoma, and cervical carcinoma)
  • •Patients with any of the following laboratory values at the time of the screening test
  • •Hematocrit < 27% (0.27 v/v)
  • •Hemoglobin < 9 g/dl (90 g/L)
  • •Potassium > 5.5 mEq/L
  • •Patients with or a history of alcohol, drug abuse, or drug dependence
  • •Patients with a history of serious adverse reactions or allergic reactions or hypersensitivity to sparsentan, angiotensin n-receptor blockers, or endothelin-receptor blockers
  • •Pregnant women, patients who may be pregnant, patients who are breastfeeding, and patients who wish to become pregnant during the study
  • •Patients who participated in another study within 28 days before the screening test
  • •Patients with a positive human immunodeficiency virus (HIV) antibody test at screening
  • •Patients with a positive hepatitis B virus surface antigen (HBsAg), hepatitis B virus surface antibody (HBsAb), or hepatitis B virus core antibody (HBcAb) test at screening. However, patients with a single positive HBs antibody due to HB vaccination can be enrolled.
  • •Patients with a positive hepatitis C virus (HCV) antibody test at screening. However, if the HCV antibody test is positive, an RNA test is performed, and if the result is negative, enrollment is allowed.
  • •Patients who donated 400 mL within 12 weeks or >= 200 mL within 4 weeks prior to obtaining consent (Contains platelets and plasma components) or who donated blood from screening to the day before the start of treatment (Day -1)
  • •Other patients for whom participation in the study was deemed inappropriate by the investigator (sub investigator)

Outcomes

Primary Outcomes

Change from baseline in urinary protein-to-creatinine ratio (UP/C)

Time Frame: 36 weeks

Based on 24 hour urine samples

Secondary Outcomes

  • Estimated percentage change in glomerular filtration rate (eGFR) 52 weeks after the onset of the acute effect(52 weeks after the onset of the acute effect)
  • Estimated percentage change in glomerular filtration rate (eGFR) 104 weeks after the onset of the acute effect(104 weeks after the onset of the acute effect)
  • Estimated glomerular filtration (eGFR) rate at Week 110 Change(Week 110)
  • Temporal change from baseline in Estimated glomerular filtration rate (eGFR) up to 110 weeks and proteinuria variables based on 24 h urine samples(up to 110 weeks)
  • Proportion of patients with documented 40% decline in eGFR, ESRD, or death

Investigators

Similar Trials

Completed
Phase 1
A phase 1 / 2 trial of AMG0001 in patients with primary lymphedema
JPRN-UMIN000011427AnGes MG, Inc.20
Unknown
Phase 2
Phase II Study of 0.15% UF-021 in patients with retinitis pigmentosaretinitis pigmentosa
JPRN-jRCT2080220721R-Tech Ueno, Ltd105
Active, not recruiting
Phase 1
A Phase 1/2 Open-label Study in Patients with Arginase I Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102Arginase 1 deficiency HyperargininemiaMedDRA version: 20.0 Level: PT Classification code 10062695 Term: Arginase deficiency System Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2017-003851-45-GBAeglea Biotherapeutics, Inc.12
Active, not recruiting
Phase 1
A Phase 1/2 Open-label Study in Patients with Arginase 1 Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102Arginase 1 deficiency HyperargininemiaMedDRA version: 20.0 Level: PT Classification code 10062695 Term: Arginase deficiency System Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2017-003851-45-PTAeglea Biotherapeutics, Inc.12
Unknown
Phase 1
Phase I Clinical Study of RG7304 in Patients with Advanced Solid Tumors
JPRN-jRCT2080221452Chugai Pharmaceutical Co., Ltd.30
Phase 3 open study of RE-021 in patients... | Clinical Trial